CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity

A large proportion (40–60%) of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer do not benefit from trastuzumab treatment, potentially due to the lack of complement-dependent cytotoxicity (CDC) activation. In the present study, the effect of complement decay...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Yang, Ya-Jun, Wang, Zhu, Liao, Juan, Liu, Mei, Zhong, Xiao-Rong, Zheng, Hong, Wang, Yan-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588148/
https://www.ncbi.nlm.nih.gov/pubmed/28928834
http://dx.doi.org/10.3892/ol.2017.6555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588148/
https://www.ncbi.nlm.nih.gov/pubmed/28928834
http://dx.doi.org/10.3892/ol.2017.6555

Ejemplares similares